2cureX AB (publ) (2CUREX.ST)
SEK 0.4
(-5.24%)
SEK 0.4
(-5.24%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -37.48 Million SEK | -5.86% |
| 2022 | -35.41 Million SEK | -603.15% |
| 2021 | 7.03 Million SEK | -53.1% |
| 2020 | 15 Million SEK | 29.96% |
| 2019 | 11.54 Million SEK | 59.39% |
| 2018 | 7.24 Million SEK | 192.53% |
| 2017 | -7.82 Million SEK | -804.64% |
| 2016 | 1.11 Million SEK | -45.17% |
| 2015 | 2.02 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -1.21 Million SEK | -327.63% |
| 2024 Q2 | -1.21 Million SEK | 0.0% |
| 2023 Q2 | -9.29 Million SEK | -0.67% |
| 2023 FY | -37.48 Million SEK | -5.86% |
| 2023 Q4 | 532 Thousand SEK | 105.3% |
| 2023 Q3 | -10.04 Million SEK | -8.14% |
| 2023 Q1 | -9.22 Million SEK | -1.65% |
| 2022 Q2 | -8.01 Million SEK | -2325.56% |
| 2022 FY | -35.41 Million SEK | -603.15% |
| 2022 Q4 | -9.07 Million SEK | -12868.57% |
| 2022 Q3 | -70 Thousand SEK | 99.13% |
| 2022 Q1 | 360 Thousand SEK | -85.38% |
| 2021 Q3 | 440 Thousand SEK | 16.09% |
| 2021 Q2 | 379 Thousand SEK | -89.91% |
| 2021 Q1 | 3.75 Million SEK | 177.41% |
| 2021 FY | 7.03 Million SEK | -53.1% |
| 2021 Q4 | 2.46 Million SEK | 459.77% |
| 2020 Q3 | 4.16 Million SEK | 22.3% |
| 2020 Q2 | 3.4 Million SEK | 30.93% |
| 2020 FY | 15 Million SEK | 29.96% |
| 2020 Q4 | -4.85 Million SEK | -216.39% |
| 2020 Q1 | 2.6 Million SEK | -45.61% |
| 2019 FY | 11.54 Million SEK | 59.39% |
| 2019 Q1 | 2.28 Million SEK | -29.46% |
| 2019 Q3 | 2.61 Million SEK | 13.57% |
| 2019 Q4 | 4.78 Million SEK | 83.3% |
| 2019 Q2 | 2.29 Million SEK | 0.52% |
| 2018 Q1 | 232 Thousand SEK | 115.79% |
| 2018 FY | 7.24 Million SEK | 192.53% |
| 2018 Q3 | 3.39 Million SEK | 318.64% |
| 2018 Q2 | 810 Thousand SEK | 249.14% |
| 2018 Q4 | 3.24 Million SEK | -4.39% |
| 2017 Q4 | -1.46 Million SEK | -278.49% |
| 2017 FY | -7.82 Million SEK | -804.64% |
| 2017 Q1 | 341 Thousand SEK | -28.36% |
| 2017 Q2 | 698 Thousand SEK | 104.69% |
| 2017 Q3 | 823 Thousand SEK | 17.91% |
| 2016 FY | 1.11 Million SEK | -45.17% |
| 2016 Q4 | 475.97 Thousand SEK | 0.0% |
| 2015 FY | 2.02 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 76.671% |
| Ziccum AB (publ) | -23.28 Million SEK | -60.985% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 110.824% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 189.71% |
| Mendus AB (publ) | 28.48 Million SEK | 231.593% |
| Genovis AB (publ.) | 54 Million SEK | 169.419% |
| Intervacc AB (publ) | -13.79 Million SEK | -171.763% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 1826.716% |
| Active Biotech AB (publ) | -1.67 Million SEK | -2138.03% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 476.262% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 239.767% |
| Aptahem AB (publ) | 2.63 Million SEK | 1525.01% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -995.791% |
| Kancera AB (publ) | -1.96 Million SEK | -1807.735% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 48784.416% |
| Fluicell AB (publ) | 1.73 Million SEK | 2256.904% |
| Saniona AB (publ) | 11.78 Million SEK | 418.199% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | -632.597% |
| Biovica International AB (publ) | 6.87 Million SEK | 645.107% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | -61.006% |
| AcouSort AB (publ) | 8.38 Million SEK | 546.859% |
| Xintela AB (publ) | 78 Thousand SEK | 48160.256% |
| Abliva AB (publ) | -35.66 Million SEK | -5.115% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 74.481% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 1435.483% |
| OncoZenge AB (publ) | 3000.00 SEK | 1249666.667% |
| Amniotics AB (publ) | -1.93 Million SEK | -1842.332% |
| CombiGene AB (publ) | -21.29 Million SEK | -76.072% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -8762.175% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 103.318% |
| Camurus AB (publ) | 1.58 Billion SEK | 102.372% |
| Corline Biomedical AB | 28.38 Million SEK | 232.089% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 69.457% |
| Isofol Medical AB (publ) | -34.41 Million SEK | -8.926% |
| I-Tech AB | 27.56 Million SEK | 235.99% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 152.835% |
| Cyxone AB (publ) | 2.61 Million SEK | 1535.733% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 1201.587% |
| Biosergen AB | -456 Thousand SEK | -8120.833% |
| Cantargia AB (publ) | -3.45 Million SEK | -986.265% |
| NextCell Pharma AB | -43.74 Million SEK | 14.312% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | -307.733% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 434.16% |
| Nanologica AB (publ) | -76 Thousand SEK | -49225.0% |
| SynAct Pharma AB | -778 Thousand SEK | -4718.38% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -19323.316% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | -190.102% |
| Lipum AB (publ) | 53 Thousand SEK | 70830.189% |
| BioInvent International AB (publ) | 71.46 Million SEK | 152.458% |
| Alzinova AB (publ) | 19.87 Million SEK | 288.623% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 203.273% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 2662.303% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -249813.333% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 2360.977% |
| Simris Alg AB (publ) | 2 Million SEK | 1967.813% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | -947.123% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 205.931% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -3473.594% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 1296.521% |